BMS-986278 is a novel next generation LPA1 antagonist currently in Phase I clinical trials. BMS-986278 is a potent and complete antagonist of LPA action at LPA1-mediated Gi, Gq, G12, and 尾-arrestin signaling pathways in both cells heterologously expressing human LPA1 and in primary human ...
This study evaluated the safety, tolerability, and PK of oral BMS-986278 in healthy participants (ppts).Methods: IM027-009 is a phase 1, double-blind, placebo (PBO)-controlled, randomized study in healthy adults. In SAD evaluation (with sentinel dosing), ppts received BMS-986278 or PBO (...